Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 June 2019 |
Main ID: |
EUCTR2016-004599-23-ES |
Date of registration:
|
04/07/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase
|
Scientific title:
|
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase |
Date of first enrolment:
|
26/07/2017 |
Target sample size:
|
102 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004599-23 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Canada
|
Germany
|
Greece
|
Israel
|
Italy
|
Spain
|
United Kingdom
|
United States
| | | | | | | |
Contacts
|
Name:
|
Isabelle Aelbrecht
|
Address:
|
516, rue Pierre et Marie Curie
31670
Labège
France |
Telephone:
|
+34932275753 |
Email:
|
isabelle.aelbrecht@genkyotex.com |
Affiliation:
|
Genkyotex Innovation SA |
|
Name:
|
Isabelle Aelbrecht
|
Address:
|
516, rue Pierre et Marie Curie
31670
Labège
France |
Telephone:
|
+34932275753 |
Email:
|
isabelle.aelbrecht@genkyotex.com |
Affiliation:
|
Genkyotex Innovation SA |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Inclusion Criteria: 1. Male or female aged 18 to 80 years, inclusive. 2. Willing and able to give written informed consent and to comply with the requirements of the study. 3. PBC diagnosis as demonstrated by the presence of > or = 2 of the following 3 diagnostic factors: -History of elevated ALP levels (> ULN) for at least 6 months -Positive anti-mitochondrial antibody (AMA) titer or if AMA negative or in low titer (< 1:80) PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex]) -Liver biopsy consistent with PBC (based on historic liver biopsy), including non-suppurative, destructive cholangitis affecting mainly the interlobular and septal bile ducts. 4. Serum ALP > or = 1.5 x ULN. 5. Serum GGT > or = 1.5 x ULN. 6. UDCA treatment for at least 6 months and stable dose for at least 3 months prior to Visit 1. 7. Subjects being treated for pruritus with colestyramine must be on a stable dose of colestyramine for at least 8 weeks prior to baseline/Day 1 (Visit 2). Subjects must be willing and able to take colestyramine at least 2 hours before or after study medication. 8. Female subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy for 4 weeks before randomization and must agree to continue strict contraception for 90 days after last administration of investigational medicinal product (IMP). Male participants with female partners of childbearing potential must be willing to use a condom and require their partner to use an additional form of adequate contraception as approved by the Investigator. This requirement begins at the time of informed consent and ends 90 days after the last administration of IMP. Male study participants must also not donate sperm from baseline until 90 days after the last administration of IMP. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 95 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 7
Exclusion criteria: 1. A positive pregnancy test or breast-feeding for female subjects. 2. Any hepatic decompensation, defined as a past or current history of hepatic encephalopathy, gastrointestinal tract bleeding due to esophageal varices, or ascites 3. International normalized ratio (INR) > 1.2 unless subject is on anticoagulant therapy. 4. ALT > 3 x ULN. 5. Total bilirubin > 1 x ULN. 6. Planned or current plasmapheresis or other extra-corporeal treatments (e.g., molecular adsorbent recirculation system (MARS)) for treatment-refractory pruritus. 7. History of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score > or = 15. 8. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma. 9. Hepatorenal syndrome (type I or II) or Screening serum creatinine > ULN XML File Identifier: rjJ7EGHMlKYcmM9gEiiQp45Uc40= Page 11/24 7. Subjects being treated for pruritus with colestyramine must be on a stable dose of colestyramine for at least 8 weeks prior to baseline/Day 1 (Visit 2). Subjects must be willing and able to take colestyramine at least 2 hours before or after study medication. 8. Female subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy for 4 weeks before randomization and must agree to continue strict contraception for up to 90 days after last administration of investigational medicinal product (IMP). Male participants with female partners of childbearing potential must be willing to use a condom and require their partner to use an additional form of adequate contraception as approved by the Investigator. This requirement begins at the time of informed consent and ends 90 days after the last administration of IMP. Male study participants must also not donate sperm from baseline until 90 days after the last administration of IMP. E.4 PRINCIPAL EXCLUSION CRITERIA (list the most important) English 1. A positive pregnancy test or breast-feeding for female subjects. 2. Any hepatic decompensation, defined as a past or current history of hepatic encephalopathy, gastrointestinal tract bleeding due to esophageal varices, or ascites 3. International normalized ratio (INR) > 1.2 unless subject is on anticoagulant therapy. 4. ALT > 3 x ULN. 5. Total bilirubin > 1 x ULN. 6. Planned or current plasmapheresis or other extra-corporeal treatments (e.g., molecular adsorbent recirculation system (MARS)) for treatment-refractory pruritus. 7. History of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score = 15. 8. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma. 9. Hepatorenal syndrome (type I or II) or Screening serum creatinine > ULN. 10. Competing etiology for liver disease (e.g., hepatitis C, active hepatitis B, non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), autoimmune hepatitis, primary sclerosing cholangitis, Gilbert's Syndrome). 11. Subjects receiving prohibited medications within 3 months of Screening (Visit 1) according to the list (a, b and c) provided in Section 6.6.2. 12. Treatment with any investigational agent within 4 weeks of Visit 1 or 5 half-lives of the investigational medicinal product (whichever is longer). 13. A history of long QT syndrome. 14. Evidenc
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
|
Primary Biliary Cholangitis MedDRA version: 20.0
Level: LLT
Classification code 10036680
Term: Primary biliary cirrhosis
System Organ Class: 100000023866
|
Intervention(s)
|
Product Code: GKT137831 Pharmaceutical Form: Capsule INN or Proposed INN: GKT137831 CAS Number: 1218942-37-0 Other descriptive name: GKT137831 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Secondary Objective: - To evaluate the safety of oral GKT137831 in comparison with placebo, in subjects with PBC. - To estimate the population pharmacokinetics (PK) of GKT137831 and explore any potential Pharmacokinetics-Pharmacodynamics (PK-PD) relationships in this subject population. - To explore any relationship between genetic parameters and therapeutic responses in a subset of subjects.
|
Timepoint(s) of evaluation of this end point: The percent change from baseline to Week 24 (Visit 7) in serum GGT. Serum GGT will be assessed during every treatment visit. (visit's 2-7)
|
Primary end point(s): Primary: - the percent change from baseline to Week 24 (Visit 7) in serum GGT.
|
Main Objective: To evaluate the efficacy of oral GKT137831 in comparison with placebo, in subjects with PBC receiving UDCA and with persistently elevated Alkaline Phosphatase (ALP).
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Timepoints of the secondary endpoints are included within the secondary objective endpoints section E.5.2 (above)
Most secondary assessments will be assessed from baseline to each visit however the ELF score and collagen fragments will be assessed from baseline to week 12 and week 24. The change in liver stiffness (FibroScan or similar technology) will be assessed from baseline to week 24.
|
Secondary end point(s): - Absolute and percent change in serum GGT from baseline to each assessment.
- Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to Weeks 12 and 24.
- Absolute and percent change in serum levels of highsensitivity C-reactive protein (hsCRP) and fibrinogen from baseline to each assessment.
- Absolute and percent change in serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and conjugated and total bilirubin, from baseline to each assessment.
- Absolute and percent change in serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), conjugated and total bilirubin, and Cytokeratin-18 (CK-18), from baseline to each assessment.
- Absolute and percent change in the Fibrosis-4 (FIB-4) and AST to Platelet Ratio Index (APRI) scores, from baseline to each assessment (FIB-4: age (years) x AST (IU/L)/(platelet count (109/L) x (ALT (IU/L)1/2, APRI: AST (IU/L)/ upper normal limit AST)x100/platelet count (10E9/L).
- Absolute and percent change in liver stiffness as assessed by transient elastography (FibroScan or similar technology), from baseline to Week 24, in patients with values at baseline and Week 24.
- Absolute and percent change in serum levels of collagen fragments indicative of collagen formation and degradation from baseline to Weeks 12 and 24.
-Absolute and percent change in total bile acids from baseline to Week 12 and 24.
|
Secondary ID(s)
|
GSN000300
|
2016-004599-23-BE
|
Source(s) of Monetary Support
|
Genkyotex Innovation SA
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|